Global Experts Unite at Suraksha Clinic and Diagnostics

News Desk, News Nation 360 : Suraksha Diagnostic Limited ("Suraksha Clinic and Diagnostics"), one of Eastern India's leading diagnostics chains, hosted an informative scientific session on 'Advances in Genetics & Reproductive Health' with eminent international experts who shared their valuable insights on the changing landscape of Prenatal, Postnatal, and Preimplantation Genetic Testing. Dr Michael Richardson, Senior Director, APAC, Yourgene Health, who discussed Yourgene Health NIPT and Confirmatory - Testing Development, Dr Xin Yue Chan, Product Specialist (Reproductive Health), APJ, Thermo Fisher Scientific, who shared his insights on CytoMicroArray Applications in Prenatal and Postnatal Genetic Analysis, and Alain Rico, Sr Product Manager, LSG, Thermo Fisher Scientific, who presented on PGT-A: Current Practices and Future Horizons in Preimplantation Genetic Testing. Recent diagnostics, led by genomics, have considerably improved detection of genetic abnormalities and rare diseases, key in India where approximately 70 million individuals suffer from rare diseases and 50-70% are among children, necessitating early intervention and genetic screening for timely medical treatment and cost management, and in 2025, India's birth rate is approximately 25 million per year, with Down syndrome (from Trisomy 21) occurring in one of every 850 newborns—equating to 30,000 to 40,000 affected births annually—while Patau syndrome (Trisomy 13) strikes in one of every 10,000 to 20,000 births and Edwards syndrome (Trisomy 18) in one of every 5,000 to 6,000 births, all of which are detectable through Non-Invasive Prenatal Testing (NIPT) that tests fetal DNA in the mother's blood, and with India's Total Fertility Rate (TFR) falling to 1.9 (below the 2.1 replacement level) per the UNFPA 2025 SOWP Report, fueled by girls receiving more education, better maternal healthcare, empowered women, greater access to contraception, delayed marriage and childbearing, and advanced fertility technologies, families with fewer births are increasingly opting for NIPT and microarray testing to guarantee healthy results, with IVF-associated PGT-A utilized to screen embryos when there is risk of miscarriage or genetic susceptibility, and the Indian market for NIPT, valued currently at $0.40 billion, is projected to grow to $1.20 billion by 2033 with a CAGR of 11.5%, as demand increases based on higher maternal age, health consciousness, better prenatal technology, and government support, with existing NIPT tests running INR 10,000 to 30,000 and selected due to low risk, increased disposable incomes, and desire for safe, healthy births. Speaking on the scientific session on ‘Advances in Genetics & Reproductive Health’, Dr Somnath Chatterjee, Chairman & Joint Managing Director, Suraksha Clinic & Diagnostics, stated that reproductive genomics has significantly altered the landscape of maternal and foetal healthcare. Suraksha Clinic and Diagnostics is a one-stop technology centre that combines new genomic techniques with professional cytogenetic interpretation to ensure the most accurate diagnosis and improved reproductive health outcomes.

Pic - Courtesy